Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-ascending-dose study of BRY10 in healthy male volunteers
jRCT2051240123Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing BRY10 single-dose arm with Placebo single-dose arm (2 arms). Primary endpoints: Adverse events, Clinical safety assessments and 1 more. Started Sep 2024; status: completed.
02
Drugs
BRY10
Beyond the preview
Go deeper on jRCT2051240123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240123.